Continues to devote entire life to public service through not-for-profit enterprises focused on the arts and education. Brand new to investing by way of very modest inheritance in a couple of handsfull of fairly conventional positions. Primary investment goal is to not lose the investment while learning about investments. At the end of the day, it would be a good thing to not be viewed as an idiot.
Seeking Alpha's product team is responsible for the development of all of our product-related projects from start to finish. These projects include the Seeking Alpha Portfolio apps on the App Store and Google Play, our Real Time email alert product, and optimization across the Seeking Alpha website.
The purpose of this profile is to allow us to share with our readers all new product developments. Please follow us on Seeking Alpha to receive updates. We look forward to your input and feedback!
SA Product Team
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
President of Almington Capital - Merchant Bankers.
Investing in publicly traded securities, private equity, real estate, venture capital.
Taking advantage of deep value opportunities, growth opportunities, and special situations across a range of asset classes and industries.
Avisol Capital Partners runs the Total Pharma Tracker Seeking Alpha Marketplace service. This is managed by Dr Asok Dutta, BVScAH and Dr Udaya Kumar Maiya, MD Oncologist. The service offers end-to-end research on both investing and trading ideas everyday, and includes a 150-stock watchlist and two 40-stock model portfolios that are continuously tracked.
Dr Dutta is a retired veterinary surgeon. He has over 40 years experience in the industry. Dr Maiya is a well-known oncologist who has 30 years in the medical field, including as Medical Director of various healthcare institutions. Both doctors are also avid private investors. They are assisted by a number of finance professionals in developing this service.
If you want to check out our service, go here - https://seekingalpha.com/author/avisol-capital-partners/research
Disclaimer - we are not investment advisors.
We are a collaboration of biotechnology insights providing investment research. Currently, we are featuring our Lucky Seven swing-trading portfolio of biotechnology stocks that present with excellent short-term risk-to-reward ratios. Unlike nearly all other services, we 1. do not overwhelm you with dozens of picks to choose from; 2. give you our top three picks; 3. consider time as money too, because it is; 4. organize our picks in a manner that reflects individual risk-tolerance; 5. hold ourselves accountable for each recommendation by keeping track of all of our trades; 6. provide insight as to when to enter a ticker and when to exit (timing is everything in biotech investing). We will also occasionally present long-term ideas, research, technical analysis, etc. At the helm of Clover is Stephen Ayers. He is a Registered Nurse who works on an intermediate care unit in a hospital and witnesses first-hand the powerful impact of medicine. He is an avid biotechnology researcher and advocater. He believes collaboration with persons of differing biotechnology angles will enrich his work. Subsequently, he has formed Clover Biotech Research to provide a platform for investors to experience several different perspectives. Clover recently welcomed Gobinath Varadappan, a biomedical engineer with big pharma experience and knowledge of clinical, regulatory, and commercial aspects of drug development. Gobinath is looking forward to making vital contributions to the team. Clover plans to secure additional advisers and writers in the future.
I am the Founder of Biotech Analysis Central, A subscription service on Seeking Alpha's Marketplace. If you want to learn more about biotech investing or you want to check out my biotech analysis you can do so with a free 2-week trial to my service. Just hit the "Learn More" button on the bottom of the Marketplace Research Tab. I have a Bachelors of Applied Science Degree In Technology Management, Industrial and Business Services Management from St. Petersburg College Florida. I have been investing in biotech stocks for many years, and I prefer to invest as a long term investor. With that In mind I seek stocks that have long term value! I primarily Like to Invest In biotechnology stocks and I accept the risks. I Write for the Healthcare Sector and Stock market in general. I contribute to Seeking Alpha, Talk Markets, and CNA Finance. I run my own biotechnology website Biotechpicklist.com
You can follow me on stocktwits.com under the name BiopharmaPro where I currently have (60,043) followers. Join me in my quest to find the best biotechnology stocks that deliver results to help patients with new treatment options. I am not afraid to find some biotech stocks to short either after results have proven a drug to be ineffective. Looking at both the negative and positive aspects of biotech investing is the best way to invest in this sector.
I am an individual investor who has been investing in common stocks for more than 40 years. With all the information available today, it is more exciting than ever. Have a degree in business adm-marketing with major study in accounting and economics. Spent over 40 years in marketing and sales in the automotive industry with a global manufacturer. U. S. Army combat veteran--awarded Bronze Star and Purple Heart.
My name is Dr Kanak Kanti De, MBBS, MD, PhD, retired medical practitioner, cancer survivor, healthcare sector investor, over 30 years' experience in the sector both in India and the United States. I write/have written on Motley Fool, SeekingAlpha, Benzinga, and on Forbes. I am consistently ranked high on TipRanks, although I don't like their ranking system. My portfolio has consistently beat the various indices for years. Email me to discuss my articles, or for just an adda (Bengali for informal chat) firstname.lastname@example.org.
Jonathan Moreland is the founder and Director of Research at InsiderInsights.com, which produces a Daily Ratings Report, Weekly Newsletter, and offers real-time insider data and analytics via its institutional strength Data Module and APIs. InsiderInsights' research and data are further available on Bloomberg terminals at ININ and APPS ININ .
Mr. Moreland is also principal of Insider Asset Management llc, a registered investment adviser in New York State, and a past contributor to TheStreet.com, Minyanville, and other financial outlets.
A fundamental analyst with an MBA in finance, Mr. Moreland identified insider data over 25 years ago as an excellent first screen to determine where to focus his research efforts. He is quoted frequently in the media for his insider analysis, and stock recommendations stemming from it. He is also author of "Profit From Legal Insider Trading" (Dearborn 2001).
Mr. Moreland is currently on a mission to get investors to expect more from insider data than the commodity feeds they rely on from their Bloomberg terminals, Yahoo!Finance, and other financial websites.
Liu is currently the CEO of Capitol Isle Partners LLC a media consulting business focusing on corporate restructuring and new business development. He is a partner in Information Central, a newsletter content provider and web marketing company. He also serves as a Senior Advisor to Goldmark Advisors, an investment banking boutique specializing in media situations. Liu has been a successful start-up and turnaround specialist in the media and publishing industry. He has spent his career advising companies in the fields of publishing, direct marketing and web-partnership marketing. In the past several years, he has consulted via Capital Isle Partners with well-known clients such as TV Guide, Primedia, Evercore Partners, Boardroom Reports and Willis Stein Partners. Before becoming a consultant, Liu has held several prestigious assignments. He was the Vice President of Consumer Marketing for American Media, Inc., publishers of The National Enquirer, STAR Magazine. Liu served as the Executive Vice President and co-founder of Lear Publishing, a consumer magazine company founded by Frances Lear (Norman Lear's ex-wife). He was also the President and Publisher of Network Publishing, the magazine division of the Providence Journal Company, and executed the hugely successful turn around of Soap Opera Digest. Liu is a long time investor focusing on value and strategic plays where his business experience in turnaround and restructuring work can be used to find and define opportunities in the market.
I am an analyst and CFA Charterholder that gained experience in the investment industry through positions as a proprietary trader and a portfolio management administrator. I began contributing to Seeking Alpha as a way to share my thoughts on the biopharmaceutical industry. I discussed ways to minimize risk in biopharmaceutical investing through conservative pipeline valuation and balance sheet analysis to identify companies presenting a compelling valuation to potential investors. I also touched on ways to apply knowledge of the markets to improve personal finance. My pieces included either stock-specific analysis or general biopharmaceutical investing discussion through my Biotech Weekly blog. My research appeared on the websites of CNBC, Seeking Alpha, Reuters, Google Finance, Morningstar, NASDAQ, and MarketWatch.
Note: Articles and comments are my own opinions, are not related to the opinions of my employer, and should not be considered investment advice. Make sure to do your own due diligence before making an investment decision. Thanks!
Jason is a small business owner that has been investing in stocks since 1989. He is a value/growth investor. Jason holds degrees in biomedical engineering and materials engineering from Rensselaer Polytechnic Institute and started his own company in 2001, thus increasing his enjoyment of life considerably. Disclaimer: Jason reminds investors to always do their own due diligence on any investment, and to consult their own financial adviser or representative when necessary. Any material provided is intended as general information only, and should not be considered or relied upon as a formal investment recommendation.
Value Digger holds MSc. in Electrical Engineering, speaks four languages and has lived in the U.S. for many years. He is a full-time, deep value investor and a well-known freelance writer who has been consistently ranked in the TOP-100 on TipRanks out of over 6,000 financial bloggers and analysts since 2012.
Specifically, he is a Seeking Alpha Author with one of the highest Followers per Article (F/A) rates. His F/A rate in Seeking Alpha exceeds 30 followers per article. Also, he is the Publisher and Editor of "The Alpha Discoverer", an insightful investment newsletter on The Maven (MVEN). Additionally, he is an Author for Stockhouse.com, Canada's #1 financial portal and one of North America's largest small cap investor communities with over 1 million unique visitors a month.
In 2014, Value Digger created a big community of deep value investors on his own website www.nathansbulletin.com. In 2015, Value Digger launched "Value Investor's Stock Club" on Seeking Alpha, a top-ranked deep value research service which includes an unparalleled, actively-managed and high-return Portfolio of unknown/underfollowed stocks. In 2017, Value Digger launched "The Alpha Discoverer", an insightful investment newsletter on TheMaven (MVEN) platform.
The Quarterly Performance Reviews PROVE his high returns and are available to his subscribers on Seeking Alpha and TheMaven. For reference, when Value Digger was managing money in the early 2000s, his Portfolio's annual ROI consistently exceeded 70%. His Premium Research is based on a comprehensive review of company-specific factors, macro conditions, competitors and the industry trends. Value Digger uses his analytical skills, goes against the grain and repeatedly discovers disconnects in a variety of sectors.
When it comes to his publicly-available picks and his free articles, Value Digger has a success rate of ~70%, an average return per recommendation of ~20% and a 5-star rating (TipRanks.com), which is the highest category quality ranking used to evaluate financial experts. TipRanks.com is a comprehensive investing tool that allows private investors and day traders to see the measured performance of anyone who publicly provides financial advice. TipRanks.com collects data, evaluates and ranks over 6,000 financial experts worldwide.
After 30 years of investing experience in the international markets (U.S., Canada, Australia, Europe), Value Digger has formulated a deep understanding of valuation analysis and his investment philosophy is firmly grounded in Ben Graham-style value-oriented opportunities that often have an assymetric risk/reward profile. On that front, he has created a unique proprietary database with thousands of publicly-traded companies per sector, which helps him spot the bargains and the bubbles before many investors find them.
I am Seeking Alpha's CEO and Editor-in-Chief. My love for the stock markets goes back to when I was a kid. Who else remembers combing through the stock quotes at the back of the business section of your local paper?
I joined Seeking Alpha in 2006 and launched Wall Street Breakfast and Market Currents, our top-of-class short-form breaking news for investors. In 2010 I became editor-in-chief and in 2015 I became CEO.
I live in Jerusalem with my wife and a bunch of exceptional kids. Most days, you'll find me making the commute from Jerusalem to Raanana. Occasionally I get to work from my home-office, from where I keep an eye on the beautiful Judean Hills.
To contact me, send me a direct message, or email me at email@example.com.
I started investing while getting my Ph.D. at McGill University. My research was on behavioral correlates of neurological control of cardiovascular function. After 25 years as a Professor, I quit to do something more exciting and more difficult: live off of my investments. For quite some time, I specialized in Canadian Oil & Gas Trusts, other high income opportunities and special situations. In 2005, I founded the Trust Intelligence website to provide research and guidance to investors trying to wean them off of relying on sell-side analysts and to understand how to do due diligence from the point of view of an investor.
My personal investment focus, and that on my website, is still on special situations and income investments in Canada and the USA. I am focused on looking at relative value and great managements with businesses that have the characteristics to give them superior potential. While I retain interesting in the petroleum & income sectors I not focus on a few biotech special situations because they can be transformative for people's health and their net worth.
Grant Zeng has over 10 years of professional experience in equity research and analysis. Grant joined Zacks Investment Research Inc. in March 2006, and currently is a senior equity analyst covering biotech/pharma industry. Before joining Zacks, Grant worked for TheStreet.com as a biotech analyst from 2005-2006. From Sept 2001 to December 2003, Grant worked for China Pacific Insurance Co. as an senior equity/fund analyst. Grant was a healthcare equity analyst with Young & Partners, LLC from Aug 2000 to September 2001. Grant had also teaching and researching experience in pharmaceutical science.
Grant Zeng obtained his MBA with a major in Finance in 2000 from McMaster University, Canada. He also holds a Master of Science in Biochemistry from the University of Western Ontario, Canada; Master of Pharmacology and Bachelor of Medicine from Second Military Medical University, China.
Grant Zeng is a Chartered Financial Analyst (CFA) charter holder.
I hold multiple undergraduate degrees with concentrated focus in the fields of Psychology, Sociology, History, and Economics. Prior to working as an independent strategist for a handful of clients, I was employed as a behavioral economist for a private London based group. Before that, I worked for domestic entities such as FBR and ACC Capital.
In terms of equities analysis, my focus is strictly on long term investments, emerging biotechnology entities, distressed or undervalued companies, and maritime commerce. In terms of market analysis, my focus is on the market implications of social and non-traditional factors. I do not discredit more traditional technical and fundamental analysis, but I value greatly the largely underrated, and often forgotten, historical evolution of capitalism and capital market psychology. Thus, some articles I write will be highly speculative and unorthodox, and will likely represent a minority opinion. Others, when undervaluation is a motivating factor for the article having been written, will be highly technical and metric based.
Also, I urge readers to consider the premise of investment horizon, and authorship intention, when reading my contributions. Many of the articles for companies which I endorse will be deemed "long term", which I generally consider to be no less than 2-3 years unless otherwise noted. Moreover, some articles are written simply to test a potential investment thesis in an effort to garner feedback about prospective positions. In the latter, the "Risk" segment of articles will be thoroughly detailed and should be heavily weighed. Many such pieces will be long "ideas", not necessarily long "recommendations" or "endorsements", and it is imperative that readers understand that prior to any assumptions being made or conclusions being drawn. Thus, I would implore readers to consider my articles carefully and thoroughly, and to ask any questions they may have pertaining to publication purpose if not otherwise clearly defined. I will always do my best to respond in a timely fashion.
Lastly, I am a fervent proponent of the value brought to investments by behavioral finance theory, and I utilize this premise in all equities analysis.
Anonymity Disclosure: I am fully cognizant of the fact that some readers question the integrity and/or accountability of anonymous contributors. Please know that my preference for privacy is a two fold consideration; (1) I remain under a revolving open contract to consult for an entity where I signed a lifetime NCND agreement. In order not to risk violating any potential terms of that agreement, now or in the future, I maintain a very low web based profile. (2) I am a proponent of unbiased analysis being openly shared among prospective investors. However, in order to ensure no collisions occur between professional patronage and personal privacy, I have elected to utilize anonymity as the barrier between the two.
I have a private small company with a few different revenue streams. I survive off of one particular stream and invest the other smaller streams into the market.
I consider myself a longterm value investor and am not risk averse. I have three seperate portfolios each holding one third of my capital.
My goal was to create a multiframed method of analysis that might allow the average retail investor to pick investments that have a high probability of doubling or tripling. I am willing to cut against the grain and take contrarian deep value bets based on price value inefficiencies. I would like to compound at 30% average yearly gains in an all of my accounts. I have had 2 years of compounding my money at over 300% in these accounts so I would be ahead of my current benchmarks. As of end of 2013.
However, I do not expect to be able to repeat my results over the long term by trading. In fact I expect to sometimes underperform the market as many of my ideas might take time to come to fruition. I will often use arbitrage opportunities or short term swings for smaller gains. I am working on fine tuning my methodology but I believe it is unique and should produce the minimum average of 30%. I am currently ahead in this race and can withstand a correction as my portfolio grows quickly. I am also willing to get defensive if need be to protect capital or even go 50%cash. I run this as a very concentrated portfolio.
One third of my capital goes in a DRIP that I average in monthly to seven companies. I change these companies yearly based on valuation and position size. I grow positions here over time and never want to hold more than 30 companies in this account.
One third goes into long term companies that I see huge growth potential.
One third is in speculative bio-tech, tech and just about anything else where I can understand the financial statement sheets on and has great possible momentum and catalysts.
I often find myself going against the current trends in the market as I see opportunity in others fear. That said I seem to invest in around 15 stocks at a time and try to focus investments into the company at the best value. I hope to earn a healthy return over the next ten years to twenty years.
I am also interested in working in the industry as a career change and am always open to advice. Anyone out there want a 36 year old intern with advanced degrees in other areas?
My main skills are finding deep value opportunities and lucrative swing trade opportunities. I seem to have found a lot of bottom entries even in today's markets. I am willing to learn, enjoy games/game theory, love to read and solve problems.
I am working on starting a limited partnership for 2015 or 2016 so that I can share my gifts with family and friends.
"What looks like a horrible disaster now could be an awesome opportunity." "Buy Cheap when the big funds and others are giving it away"
All the Best,
I'm a radiologist by trade, but the goal is to leverage that medical knowledge as a competitive advantage in the markets. I aim to include all of the following in my analyses to ensure high quality: 1) quantitative estimates; 2) new information or inferences that are not already disseminated throughout the market; and 3) hypotheses that are testable, i.e. can be proved right or wrong. I have a serious allergy to question marks and will never, ever include one in an article title.
My dream is to co-found a biotech and bring a cure from the lab to the bedside. In the meantime, saving lives in clinical practice is a perfectly acceptable alternative.
Please note that all opinions I express on this website reflect my personal beliefs only and are completely independent of my current or past employers and/or affiliated institutions.
Trader of equities and options for over 12 years. Proprietary trading strategy involving options and biotech with a very high win to loss ratio. SMID cap biotech. Passionate about science and cooking.
"Win or lose, everybody gets what they want out of the market. Some people seem to like to lose, so they win by losing money."
Full-Time individual investor. MD degree. Trade daily. Stocks and options.
Core is biopharma/ biotech, but have been selling down and diversifying. Of late bearish on the US and international markets, and changing my investment strategy due to irrational exuberance. Now have PUT LEAPs on currencies, Asian economies, SPY, retail and infrastructure, and banks. Long diversification-- tech, software, metals, and a few bonds.
It is very hard or impossible to time the broad market consistently — there are no famous investors that got rich by consistently knowing what the broad market would do next. This only makes sense, as there are just too many variables in the broad market. But there are many famous investors who got rich analyzing individual securities, and this is where you should put your focus. You can get an edge in individual securities. Joe Springer was the number 1 ranked stock analyst in the world by tipranks.com. Joe is a Certified Technical Trainer, and enjoys teaching about the stock market as well as managing portfolios. If you would like to follow Joe on Twitter, his handle is @JoeSpringer.